Drug Cost Control in Oncology

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

Following President Donald Trump's most favored nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.

In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.

The tool could make it easier for clinicians to rule out melanoma without the need for excision.